Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis

scientific article published on 12 March 2013

Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1013604887
P356DOI10.1007/S10549-013-2460-Y
P698PubMed publication ID23479421

P50authorMichael P. LuxQ37372079
Stefan P RennerQ51833341
Alexander HeinQ52723502
Peter A. FaschingQ64005064
Matthias W. BeckmannQ72940290
Lothar HaeberleQ87976657
Arndt HartmannQ89782316
Michael G SchrauderQ90107267
Katharina HeusingerQ114387418
Christian M BayerQ124154078
P2093author name stringChristian R Loehberg
Mayada R Bani
Sebastian M Jud
Falk C Thiel
David L Wachter
Katrin Almstedt
Carolin C Hack
Jutta Heimrich
Michaela Brunner
P2860cites workZNF703 gene amplification at 8p12 specifies luminal B breast cancerQ24293333
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epitheliumQ24293658
Comprehensive molecular portraits of human breast tumoursQ24630844
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancerQ33813431
Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasisQ33903716
Estrogen and progestin regulation of cell cycle progressionQ33923687
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studiesQ33984087
Clinical course and prognostic factors following bone recurrence from breast cancerQ34065927
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentQ34074094
Receptor conversion in distant breast cancer metastasesQ34989060
Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor lossQ35082619
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosisQ35546265
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupQ35552069
Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumorsQ35558018
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisQ35558914
The biology of progesterone receptor in the normal mammary gland and in breast cancerQ35868802
Survival after first recurrence of breast cancer. The Miami experienceQ36215855
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerQ36393082
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.Q36924473
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerQ37198196
Prognostic factors in 1,038 women with metastatic breast cancerQ37321930
Ki67 in breast cancer: prognostic and predictive potentialQ37691691
Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinasesQ40504026
Construction and validation of a practical prognostic index for patients with metastatic breast cancerQ40851122
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.Q43447818
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyQ43542643
Progesterone receptor status of breast cancer metastasesQ43893980
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo RegisterQ44248479
Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancerQ44287591
Impact of metastatic estrogen receptor and progesterone receptor status on survivalQ46382088
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.Q50510241
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.Q51652478
Multivariate analysis of prognostic factors in metastatic breast cancer.Q52699716
Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy.Q54400297
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.Q54519817
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.Q54614183
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)899-908
P577publication date2013-03-12
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titlePrognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis
P478volume138

Reverse relations

cites work (P2860)
Q38374808ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis
Q35054455Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Q27014939Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies
Q49796329Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Q36273328Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast
Q36892788Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
Q53599540Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Q37309686SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
Q42599064Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors
Q35619770The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Q96432540Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer
Q44521334Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility
Q52848499[New prognostic and predictive markers for breast cancer].

Search more.